Your browser doesn't support javascript.
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Einstein (Sao Paulo) ; 17(2): eGS4414, 2019 Mar 07.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30843996
ABSTRACT

OBJECTIVE:

To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation.

METHODS:

We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects.

RESULTS:

Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted Life Years. Abiraterone led to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel. The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.379,42 for abiraterone compared to docetaxel, respectively.

CONCLUSION:

The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness.
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Análise Custo-Benefício / Antineoplásicos Hormonais / Docetaxel / Antagonistas de Androgênios / Androstenos Tipo de estudo: Avaliação econômica em saúde Aspecto clínico: Terapia Limite: Humanos / Masculino País/Região como assunto: América do Sul / Brasil Idioma: Inglês / Português Revista: Einstein (Sao Paulo) Ano de publicação: 2019 Tipo de documento: Artigo País de afiliação: Brasil